Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

2,713 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Systemic safety of bevacizumab versus ranibizumab for neovascular age-related macular degeneration.
Moja L, Lucenteforte E, Kwag KH, Bertele V, Campomori A, Chakravarthy U, D'Amico R, Dickersin K, Kodjikian L, Lindsley K, Loke Y, Maguire M, Martin DF, Mugelli A, Mühlbauer B, Püntmann I, Reeves B, Rogers C, Schmucker C, Subramanian ML, Virgili G. Moja L, et al. Among authors: rogers c. Cochrane Database Syst Rev. 2014 Sep 15;9(9):CD011230. doi: 10.1002/14651858.CD011230.pub2. Cochrane Database Syst Rev. 2014. PMID: 25220133 Free PMC article. Review.
Pharmacogenetic associations with vascular endothelial growth factor inhibition in participants with neovascular age-related macular degeneration in the IVAN Study.
Lotery AJ, Gibson J, Cree AJ, Downes SM, Harding SP, Rogers CA, Reeves BC, Ennis S, Chakravarthy U; Alternative Treatments to Inhibit VEGF in Patients with Age-Related Choroidal Neovascularisation (IVAN) Study Group. Lotery AJ, et al. Among authors: rogers ca. Ophthalmology. 2013 Dec;120(12):2637-2643. doi: 10.1016/j.ophtha.2013.07.046. Epub 2013 Sep 23. Ophthalmology. 2013. PMID: 24070809 Clinical Trial.
Cost-effectiveness of ranibizumab and bevacizumab for age-related macular degeneration: 2-year findings from the IVAN randomised trial.
Dakin HA, Wordsworth S, Rogers CA, Abangma G, Raftery J, Harding SP, Lotery AJ, Downes SM, Chakravarthy U, Reeves BC; IVAN Study Investigators. Dakin HA, et al. Among authors: rogers ca. BMJ Open. 2014 Jul 29;4(7):e005094. doi: 10.1136/bmjopen-2014-005094. BMJ Open. 2014. PMID: 25079928 Free PMC article. Clinical Trial.
Systemic safety of anti-VEGF drugs: a commentary.
Scott LJ, Chakravarthy U, Reeves BC, Rogers CA. Scott LJ, et al. Among authors: rogers ca. Expert Opin Drug Saf. 2015 Mar;14(3):379-88. doi: 10.1517/14740338.2015.991712. Epub 2014 Dec 9. Expert Opin Drug Saf. 2015. PMID: 25489638 Review.
Liberal or Restrictive Transfusion after Cardiac Surgery.
Reeves BC, Rogers CA, Murphy GJ. Reeves BC, et al. Among authors: rogers ca. N Engl J Med. 2015 Jul 9;373(2):193. doi: 10.1056/NEJMc1505810. N Engl J Med. 2015. PMID: 26154794 Free article. No abstract available.
2,713 results